FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310366636> ?p ?o ?g. }

• W4310366636 endingPage "100647" @default.
• W4310366636 startingPage "100647" @default.
• W4310366636 abstract "We analyzed the FGF/FGFR and co-alteration cancer landscape, hypothesizing that combination therapy might be useful in the presence of co-drivers.We describe FGF/FGFR-altered pathways, prognosis, and co-alterations [cBioPortal (N = 7574)] and therapeutic outcomes [University of California San Diego Molecular Tumor Board (MTB) (N = 16)].Patients whose cancers harbored FGF/FGFR alterations (N = 1074) versus those without them (N = 6500) had shorter overall survival (OS) (median: 23.1 versus 26.4 months, P = 0.038) (cBioPortal). Only 6.1% (65/1074 patients) had no pathogenic co-alterations accompanying FGF/FGFR axis abnormalities. The most frequently co-altered pathways/genes involved: TP53 (70%); cell cycle (58%); PI3K (55%); and receptor tyrosine kinases and mitogen-activated protein kinase (MAPK) (65%). Harboring alterations in both FGF/FGFR and in the TP53 pathway or in the cell cycle pathway correlated with shorter OS (versus FGF/FGFR-altered without those co-altered signals) (P = 0.0001 and 0.0065). Four of 16 fibroblast growth factor receptor (FGFR) inhibitor-treated patients presented at MTB attained durable partial responses (PRs) (9, 12, 22+, and 52+ months); an additional two, stable disease (SD) of ≥6 months (13+ and 15 months) [clinical benefit rate (SD ≥ 6 months/PR) = 38%]. Importantly, six patients with cyclin pathway co-alterations received the CDK4/6 inhibitor palbociclib (75 mg p.o. 3 weeks on, 1 week off) and the multikinase FGFR inhibitor lenvatinib (10 mg p.o. daily); three (50%) achieved a PR [9 (ovarian), 12 (biliary), and 52+ months (osteosarcoma)]. Palbociclib and lenvatinib were tolerated well.FGF/FGFR alterations portend a poor prognosis and are frequently accompanied by pathogenic co-aberrations. Malignancies harboring co-alterations that activate both cyclin and FGFR pathways can be co-targeted by CDK4/6 and FGFR inhibitors." @default.
• W4310366636 created "2022-12-09" @default.
• W4310366636 creator A5004939785 @default.
• W4310366636 creator A5005618779 @default.
• W4310366636 creator A5008442400 @default.
• W4310366636 creator A5018234365 @default.
• W4310366636 creator A5018352586 @default.
• W4310366636 creator A5023542992 @default.
• W4310366636 creator A5053481267 @default.
• W4310366636 creator A5059316608 @default.
• W4310366636 creator A5062107881 @default.
• W4310366636 creator A5067306632 @default.
• W4310366636 creator A5086626483 @default.
• W4310366636 date "2022-12-01" @default.
• W4310366636 modified "2023-10-14" @default.
• W4310366636 title "Targeting the FGF/FGFR axis and its co-alteration allies" @default.
• W4310366636 cites W1566932673 @default.
• W4310366636 cites W1861063348 @default.
• W4310366636 cites W1861759122 @default.
• W4310366636 cites W1864344361 @default.
• W4310366636 cites W1960850967 @default.
• W4310366636 cites W1988476050 @default.
• W4310366636 cites W1994487360 @default.
• W4310366636 cites W2011993967 @default.
• W4310366636 cites W2055560819 @default.
• W4310366636 cites W2104041621 @default.
• W4310366636 cites W2104287359 @default.
• W4310366636 cites W2106465830 @default.
• W4310366636 cites W2114843025 @default.
• W4310366636 cites W2116215301 @default.
• W4310366636 cites W2144208206 @default.
• W4310366636 cites W2149441684 @default.
• W4310366636 cites W2160981405 @default.
• W4310366636 cites W2161608625 @default.
• W4310366636 cites W2165267819 @default.
• W4310366636 cites W2276287001 @default.
• W4310366636 cites W2550856922 @default.
• W4310366636 cites W2581395526 @default.
• W4310366636 cites W2595713273 @default.
• W4310366636 cites W2613362156 @default.
• W4310366636 cites W2614443510 @default.
• W4310366636 cites W2898174432 @default.
• W4310366636 cites W2938206352 @default.
• W4310366636 cites W2938634307 @default.
• W4310366636 cites W2964014383 @default.
• W4310366636 cites W2979035301 @default.
• W4310366636 cites W2980125816 @default.
• W4310366636 cites W2994108931 @default.
• W4310366636 cites W2997598382 @default.
• W4310366636 cites W3006012565 @default.
• W4310366636 cites W3007076179 @default.
• W4310366636 cites W3010944770 @default.
• W4310366636 cites W3019266095 @default.
• W4310366636 cites W3028725009 @default.
• W4310366636 cites W3087426855 @default.
• W4310366636 cites W3088083750 @default.
• W4310366636 cites W3089562193 @default.
• W4310366636 cites W3125289280 @default.
• W4310366636 cites W3135293426 @default.
• W4310366636 cites W3192574431 @default.
• W4310366636 cites W3203792331 @default.
• W4310366636 cites W4250636261 @default.
• W4310366636 doi "https://doi.org/10.1016/j.esmoop.2022.100647" @default.
• W4310366636 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36455506" @default.
• W4310366636 hasPublicationYear "2022" @default.
• W4310366636 type Work @default.
• W4310366636 citedByCount "3" @default.
• W4310366636 countsByYear W43103666362023 @default.
• W4310366636 crossrefType "journal-article" @default.
• W4310366636 hasAuthorship W4310366636A5004939785 @default.
• W4310366636 hasAuthorship W4310366636A5005618779 @default.
• W4310366636 hasAuthorship W4310366636A5008442400 @default.
• W4310366636 hasAuthorship W4310366636A5018234365 @default.
• W4310366636 hasAuthorship W4310366636A5018352586 @default.
• W4310366636 hasAuthorship W4310366636A5023542992 @default.
• W4310366636 hasAuthorship W4310366636A5053481267 @default.
• W4310366636 hasAuthorship W4310366636A5059316608 @default.
• W4310366636 hasAuthorship W4310366636A5062107881 @default.
• W4310366636 hasAuthorship W4310366636A5067306632 @default.
• W4310366636 hasAuthorship W4310366636A5086626483 @default.
• W4310366636 hasBestOaLocation W43103666361 @default.
• W4310366636 hasConcept C101544691 @default.
• W4310366636 hasConcept C121608353 @default.
• W4310366636 hasConcept C126322002 @default.
• W4310366636 hasConcept C134018914 @default.
• W4310366636 hasConcept C170493617 @default.
• W4310366636 hasConcept C184235292 @default.
• W4310366636 hasConcept C2776264508 @default.
• W4310366636 hasConcept C2779761222 @default.
• W4310366636 hasConcept C42362537 @default.
• W4310366636 hasConcept C502942594 @default.
• W4310366636 hasConcept C71924100 @default.
• W4310366636 hasConcept C74373430 @default.
• W4310366636 hasConcept C82867764 @default.
• W4310366636 hasConcept C86803240 @default.
• W4310366636 hasConcept C95444343 @default.
• W4310366636 hasConceptScore W4310366636C101544691 @default.
• W4310366636 hasConceptScore W4310366636C121608353 @default.

• next